Clinical trial
Memantine and Naltrexone Treatment for Opioid Dependence
NCT00125515 · New York State Psychiatric Institute, Other · Completed
Key facts
| NCT number | NCT00125515 |
|---|---|
| Title | Memantine and Naltrexone Treatment for Opioid Dependence |
| Official title | Evaluation of NMDA Antagonist for Opiate Dependence |
| Acronym | NAMHS-1 |
| Lead sponsor | New York State Psychiatric Institute, Other |
| Collaborators | National Institute on Drug Abuse (NIDA) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Opioid Dependence |
| Intervention type | Drug |
| Interventions | Memantine, Naltrexone |
| Enrollment | 81 |
| Start date | Jun 1, 2005 |
| Primary completion | Aug 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Aug 1, 2005 |
| Last update posted | Jun 18, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: